A Phase II, Prospective, Open Label Study (PO-MMM-PI-0011) to Determine the Safety and Efficacy of Pomalidomide (CC-4047) in Subjects With Primary, Post Polycythemia Vera, or Post Essential Thrombocythemia Myelofibrosis (PMF; Post-PV MF, or Post-ET MF)

Trial Profile

A Phase II, Prospective, Open Label Study (PO-MMM-PI-0011) to Determine the Safety and Efficacy of Pomalidomide (CC-4047) in Subjects With Primary, Post Polycythemia Vera, or Post Essential Thrombocythemia Myelofibrosis (PMF; Post-PV MF, or Post-ET MF)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Oct 2016

At a glance

  • Drugs Pomalidomide (Primary) ; Prednisone
  • Indications Myelofibrosis
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 13 Apr 2016 Planned primary completion date changed from 1 Aug 2017 to 1 Aug 2018 as reported by ClinicalTrials.gov.
    • 21 Apr 2015 Planned primary completion date changed from 1 Aug 2016 to 1 Aug 2017 as reported by ClinicalTrials.gov record.
    • 15 May 2013 Planned end date changed from 1 Aug 2014 to 1 Aug 2015 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top